Nubriveo (Brivaracetam)

Brivaracetam, the active ingredient in Nubriveo, is an antiepileptic presented as a strength/form for oral use. It treats focal onset seizures in patients who require adjunctive therapy. GNH USA supplies Nubriveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Nubriveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Brivaracetam is an antiepileptic medication that acts on neuronal excitability associated with seizure activity.

- Focal onset seizures: Provides adjunctive seizure control when added to existing therapy. - Partial epilepsy: Reduces seizure frequency in patients with refractory partial epilepsy. - Adjunct therapy: Enhances overall seizure management as part of combination treatment.

Adverse reactions to brivaracetam are generally mild to moderate and vary among individuals.

Common Side Effects: - Dizziness - Fatigue - Headache - Nausea - Somnolence - Irritability

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Mood changes including depression or suicidal thoughts - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic enzyme elevation - Cardiac arrhythmia - Respiratory depression

When prescribing brivaracetam, clinicians should consider several safety aspects.

- Renal impairment: Adjust dose in patients with severe renal dysfunction. - Hepatic impairment: Use caution in patients with liver disease. - Concomitant depressants: Monitor for enhanced sedation. - Pregnancy: Evaluate risk‑benefit, as safety data are limited. - Breastfeeding: Weigh potential infant exposure against maternal benefit. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Brivaracetam may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: May lower brivarine levels, reducing seizure control. - Phenytoin: Increases metabolism of brivaracetam, potentially decreasing effectiveness.

Moderate Interactions (Monitor Closely): - Valproate: May increase brivaracetam plasma concentrations. - Benzodiazepines: Additive central nervous system depression. - Alcohol: Enhances sedative effects and dizziness. - CYP3A4 inhibitors: May raise brivaracetam levels modestly. - CYP3A4 inducers: May reduce brivaracetam exposure.